

DAFTAR PUSTAKA

1. Duan B, Zhao Y, Bai J, Wang J, et al. Colorectal Cancer An Overview Gastrointestinal Cancers. Exon. 2022;11(22):1-87.doi.org/10.36255/exon-publications-gastrointestinal- cancers.
2. GLOBOCAN Global Cancer Observatory. All Cancer [Internet]. 2020 [cited 27 September 2023]. Available from: <https://gco.iarc.fr/today/>.
3. Minhajat R, Benyamin A.F, Miskad U.A. The Relationship Between Histopathological Grading and Metastasis in Colorectal Carcinoma Patients. Nusantara Medical Science Journal. 2020;5(2):50-9.
4. Jin Z, Sinicrope F A. Prognostic and predictive values of mismatch repair deficiency in non-metastatic colorectal cancer. Cancers. 2021; 13(2):1–16.
5. Malki A, Elruz R, Gupta I, Allouch A, Vranic S, et al. Molecular Mechanisms of Colon Cancer Progression and Metastasis Recent Insights and Advancements. International Journal of Molecular Sciences.2021; 22(1):1–24.
6. Argiles J, Tabernero R, Labianca D, Hochhauser R, Salazar, et al. Localised colon cancer ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology.2020;31(10),1291–1305.
7. Zeller J, Lynm C, Glass M. Colon cancer. Jama. 2006; 296(12):552. doi: 10.1001/jama.296.12.1552.
8. Yan sun, Shu Z, Desen W, Jin G, Jiaping W et al. National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version). Chinese Journal of Cancer Research. 2020;32(4);415.
9. Nguyen T, Duong, H. Q. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. Oncology letters. 2018; 16(1), 9-18.
10. Swiderska M, Choromańska B, Dą browska, E, Konarzewska D, Choromańska K., et al. The diagnostics of colorectal cancer. Contemporary Oncology. 2014;18(1),1.
11. Richman, S. Deficient mismatch repair: Read all about it (Review)', International Journal of Oncology.2015;47(4), pp. 1189–1202.



h, T, Handorf E, Meyer J , Hall M, Esnaola N. Mismatch Repair
 deficiency Testing in Patients With Colorectal Cancer and Nonadherence to

Testing Guidelines in Young Adults. JAMA Oncology.2018;205;4(2).

13. Wang B, Li F, Zhou X, Ma Y, Fu W. Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis. World J. Surg. Oncol.2019;17;169.
14. Koopman, M, Van kriecken, Gam K, Mekenkamp, Litenberg et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. British Journal of Cancer.2009; 100(2), pp. 266–273.
15. Cong Li, Fangqi liu, Dan Huang, Yuchen wu, Zhimin wang et al. The correlation between DNA mismatch repair status and the clinicopathological and molecular features of Chinese sporadic colorectal cancer. Translational Cancer Research.2020;9(1),pp.137–144.
16. Saberzadeh Ardestani B, Jeremy C Jones, Joleen M Hubbard, Robert R McWilliams, Thorvardur R Halfdanarson, et al. Association between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated with First-line Pembrolizumab. JAMA Network Open. 2023; 6(2):E230400.
17. Ye SB, Yi-Kan Cheng, Lin Zhang, Yi-Feng Zou, Ping Chen, et al. Association of mismatch repair status with survival and response to neoadjuvant chemoradiotherapy in rectal cancer. npj Precision Oncology. 2020;4(1).
18. Zhang C, Yixiang, Kemin, Zhaoce, Ran X, et al. Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods. BMC Cancer.2022;22(1):1–12.
19. Frank A. Sinicrope. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol. 2013;7(3): 174–177.
20. Zhaohui Jin, Frank A. Sinicrope. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. J Clin Oncol 2022;40:2735-2750.
21. Haszel L, Naureen S, Rille P, Marco G. Advances in immunotherapy for MMR proficient colorectal cancer. Elsevier. 2022;26(10):111.
22. Chao H, Shu C, Hong Yi, Shih C, Ching Y et al. The risk factor affecting survival in colorectal cancer in Taiwan. Iran J Public Health. 2018;47(4):pp 30.



23. Bijan MD, Azadeh S. An overview of colorectal cancer survival rate and prognosis in Asia. *Word Journal of Gastrointestinal Oncology*.2012.15(4). pp 71-75.
24. Koen Z, Frederieke H, Van der B, Cornelis JA, Emeren W, et al. Survival of patients with deficient mismatch repair versus proficient mismatch repair metastatic colorectal cancer receiving curative intent local treatment of metastasis in a nationwide cohort. *Annals of surgical oncology*. 2023.30: 6762-6770.
25. Shin K, Andre, Kim TW, Vittrup J, Jensen L.H, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H) mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC): 5 year follow up of the randomized phase III KEYNOTE-177 study. *Annals of oncology Journal*. 2023.34;S1272.
26. Peltola K. Role of DNA mismatch repair defect in the pathogenesis of human cancer. *Journal of Clinical Oncology*.2003. 15(3).pp1174-1179.
27. Eleftheria M, Katarina L, Nena K, Miriam W, Manuela L.Impact of Comorbidities at diagnosis on the 10 year colorectal cancer net survival a population base study.*Elsevier*.2021,14(4):1877.
28. American Cancer Society. *Cancer Facts & Figures 2024*. Atlanta : American Cancer Society; 2024.

